These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 9437561

  • 21. Levonorgestrel implant use among adolescents.
    Mashburn M.
    J Pediatr Health Care; 1994; 8(6):255-60. PubMed ID: 7799199
    [Abstract] [Full Text] [Related]

  • 22. Endometrial angiogenic response in Norplant users.
    Subakir SB, Hadisaputra W, Handoyo AE, Affandi B.
    Hum Reprod; 1996 Oct; 11 Suppl 2():51-5. PubMed ID: 8982746
    [Abstract] [Full Text] [Related]

  • 23. New concepts in contraception: Norplant subdermal implant.
    Lynn MM, Holdcroft C.
    Nurse Pract; 1992 Mar; 17(3):85-9. PubMed ID: 1565306
    [Abstract] [Full Text] [Related]

  • 24. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S, WHO Study Group on Contraceptive Implants for Women.
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [Abstract] [Full Text] [Related]

  • 25. Use of Norplant implants in a New York City clinic population.
    Gerber S, Westhoff C, Lopez M, Gordon L.
    Contraception; 1994 Jun; 49(6):557-64. PubMed ID: 8070260
    [Abstract] [Full Text] [Related]

  • 26. Assessing the acceptability of Norplant contraceptive in four patient populations.
    Dugoff L, Jones OW, Allen-Davis J, Hurst BS, Schlaff WD.
    Contraception; 1995 Jul; 52(1):45-9. PubMed ID: 8521714
    [Abstract] [Full Text] [Related]

  • 27. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A, Brache V, Tejada AS, Cochon L, Alvarez-Sanchez F.
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [Abstract] [Full Text] [Related]

  • 28. Effectiveness of Norplant implants among Thai women in Bangkok.
    Chompootaweep S, Kochagarn E, Sirisumpan S, Tang-usaha J, Theppitaksak B, Dusitsin N.
    Contraception; 1996 Jan; 53(1):33-6. PubMed ID: 8631187
    [Abstract] [Full Text] [Related]

  • 29. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
    Sivin I, Stern J, Diaz J, Diaz MM, Faundes A, el Mahgoub S, Diaz S, Pavez M, Coutinho E, Mattos CE.
    Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
    [Abstract] [Full Text] [Related]

  • 30. Subjective perception of bleeding and serum ferritin concentration in long-term users of Norplant.
    Faundes A, Tejada AS, Brache V, Alvarez F.
    Contraception; 1987 Feb; 35(2):189-96. PubMed ID: 3109804
    [Abstract] [Full Text] [Related]

  • 31. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
    Boonkasemsanti W, Reinprayoon D, Pruksananonda K, Niruttisard S, Triratanachat S, Leepipatpaiboon S, Wannakrairot P.
    Hum Reprod; 1996 Oct; 11 Suppl 2():115-23. PubMed ID: 8982753
    [Abstract] [Full Text] [Related]

  • 32. Subdermal contraceptive implants.
    Peralta O, Diaz S, Croxatto H.
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):223-6. PubMed ID: 7626459
    [Abstract] [Full Text] [Related]

  • 33. Experience with side effects and health risks associated with Norplant implant use in adolescents.
    Rosenthal SL, Biro FM, Kollar LM, Hillard PJ, Rauh JL.
    Contraception; 1995 Nov; 52(5):283-5. PubMed ID: 8585884
    [Abstract] [Full Text] [Related]

  • 34. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
    Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, Hubacher D, WHO study group on subdermal contraceptive implants for women.
    Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
    [Abstract] [Full Text] [Related]

  • 35. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
    Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C.
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
    [Abstract] [Full Text] [Related]

  • 36. Comparative assessment of the effects of subdermal levonorgestrel implant system and long acting progestogen injection method on lipid metabolism.
    Anwar M, Soejono SK, Maruo T, Abdullah N.
    Asia Oceania J Obstet Gynaecol; 1994 Mar; 20(1):53-8. PubMed ID: 8172528
    [Abstract] [Full Text] [Related]

  • 37. Factors associated with elective Norplant removal in black and white women.
    Opara JU, Ernst FA, Gaskin H, Smith L, Nevels HV.
    J Natl Med Assoc; 1997 Apr; 89(4):237-40. PubMed ID: 9145628
    [Abstract] [Full Text] [Related]

  • 38. Norplant-2 subdermal contraceptive system: experience in Taiwan.
    Lee TY, Yang YS, Tseng LH, Ko TM, Hsu MC, Chuang SM.
    J Formos Med Assoc; 1993 May; 92(5):446-50. PubMed ID: 8104598
    [Abstract] [Full Text] [Related]

  • 39. Characteristics and experiences of American women electing for early removal of contraceptive implants.
    Frank ML, Ditmore JR, Ilegbodu AE, Bateman L, Poindexter AN.
    Contraception; 1995 Sep; 52(3):159-65. PubMed ID: 7587187
    [Abstract] [Full Text] [Related]

  • 40. Continuation rates of long-acting methods of contraception. A comparative study of Norplant implants and intrauterine devices.
    Fleming D, Davie J, Glasier A.
    Contraception; 1998 Jan; 57(1):19-21. PubMed ID: 9554246
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.